RenovoRx Inc
Stock Chart, Company Information, and Scan Results
$1.15(as of Oct 23, 3:59 PM EST)
Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.
RenovoRx Inc Company Information, Fundamentals, and Technical Indicators
Stock Price$1.15
Ticker SymbolRNXT
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees10
CountyUSA
Market Cap$41.4M
EBIDTA-11.4M
P/E Ratio-3.94
Forward P/E Ratio0.00
Earnings per Share-0.38
Profit Margin-686.02%
RSI47.60
Shares Outstanding36.6M
ATR0.10
52-Week High1.69
Volume99,440
52-Week Low0.75
Book Value10.6M
P/B Ratio3.95
Upper Keltner1.42
P/S Ratio63.54
Lower Keltner0.97
Next Earnings Date11/17/2025
Cash Surplus10.8M
Next Ex-Dividend DateUnknown
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Mountain View, California.
Join Our Free Email List
Get emails from us about ways to potentially make money in the stock market.